Palifermin: AMJ 9701, KGF - Amgen, recombinant human keratinocyte growth factor, rHu-KGF

被引：0

作者：

不详

机构：

来源：

Drugs in R & D | 2004年 / 5卷 / 6期

关键词：

Lipase; Placebo Recipient; Metastatic Colorectal Cancer; Oral Mucositis; Serum Amylase;

D O I：

10.2165/00126839-200405060-00008

中图分类号：

学科分类号：

摘要：

Amgen is developing a recombinant human form of keratinocyte growth factor (rHu-KGF) called palifermin [AMJ 9701]. Keratinocyte growth factor (KGF, fibroblast growth factor 7, FGF-7) is a form of an endogenous epithelial tissue growth factor that stimulates the growth of cells on the surface of the gastrointestinal tract. Palifermin is being developed for oral mucositis (stomatitis), for which it is undergoing review by the US FDA. At BioSquare-2004, Biovitrum stated that it has entered into an agreement with Amgen, under which Biovitrium has co-promotion rights to palifermin in Nordic countries, including Scandinavia and Iceland. Amgen also plans to investigate the efficacy and safety of palifermin in patients with oral mucositis associated with other forms of chemotherapy. Amgen has stated that palifermin is also undergoing phase II trials in patients with solid tumours. © 2004 Adis Data information BV. All rights reserved.

引用

页码：351 / 354

页数：3

共 9 条

[1]

Durrant S., Pico J.L., Schmitz N., Et al., A phase I study of recombinant human keratinocyte growth factor in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation, Blood, 94, SUPPL. 1 and PART 1, (1999)

[2]

Meropol N.J., Gutheil J., Pelley R., Et al., Keratinocyte growth factor as a mucositis protectant: A randomized phase I trial, 36th Annual Meeting of the American Society of Clinical Oncology, 19, (2000)

[3]

Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources, (2003)

[4]

Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients, (2003)

[5]

Panoskaltsis-Mortari A., Lacey D.L., Vallera D.A., Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice, Blood, 92, pp. 3960-3967, (1998)

[6]

Amgen's KGF shows preliminary efficacy in preventing chemotherapy-induced severe oral mucositis, (2001)

[7]

Amgen Announces Positive Results of Phase 3 Study for rHu-KGF, (2003)

[8]

Stiff P., Bensinger W., Emmanouilides C., Et al., Treatment of mucositis with palifermin improves patient function and results in a clinically meaningful reduction in mouth and throat soreness: Phase 3 results, Blood, 102, 11 PART 1, (2003)

[9]

Emmanouilides C., Spielberger R., Stiff P., Et al., Palifermin treatment of mucositis in transplant patients reduces health resource use: Phase 3 results, Blood, 102, 11 PART 1, pp. 251-252, (2003)

← 1 →